Overview
Nathalie Dupre-Boiret practices practicing medicine in Clermont-ferrand, France.
Her clinical expertise encompasses Chronic Myelogenous Leukemia (CML) and Leukemia.
She is actively involved in clinical research, co-authoring 8 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Nathalie Dupre-Boiret
Is Nathalie Dupre-Boiret a top-rated expert for Chronic Myelogenous Leukemia (CML)?
MediFind is an objective health platform that identifies experts based on real-world data. Nathalie Dupre-Boiret is classified as an Experienced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Nathalie Dupre-Boiret participate in research or clinical trials?
Yes. Nathalie Dupre-Boiret has published 8 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Nathalie Dupre-Boiret's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Chronic Myelogenous Leukemia (CML)Ms. Dupre-Boiret isExperienced. Learn about Chronic Myelogenous Leukemia (CML).
- LeukemiaMs. Dupre-Boiret isExperienced. Learn about Leukemia.